Mission Statement

Founded in 2008 with headquarters in Montreal, Quebec, Traffick Therapeutics Inc is dedicated to the development of novel small molecules able to chaperone defective proteins as they traffic from the endoplasmic reticulum where they are made to the surface of cells where they function, for example, as ion channels. These novel small molecules could be used in the treatment of cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD).